Skip to main content

Compass Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

CMPX$0.84+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

24.1*Power of Attorney (included on signature page)

POWER OF ATTORNEY AND SIGNATURES

Each person whose individual signature appears below hereby authorizes and appoints Thomas J. Schuetz, Barry Shin and Carl L. Gordon, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Thomas J. SchuetzChief Executive Officer and Vice Chair of the Board (Principal Executive Officer)February 27, 2025
Thomas J. Schuetz
/s/ Barry ShinChief Financial Officer (Principal Financial Officer)February 27, 2025
Barry Shin
/s/ Neil LernerChief Accounting Officer (Principal Accounting Officer)February 27, 2025
Neil Lerner
/s/ Carl L. GordonChair of the BoardFebruary 27, 2025
Carl L. Gordon
/s/ Phil FerneauDirectorFebruary 27, 2025
Phil Ferneau
/s/ Mary Ann GrayDirectorFebruary 27, 2025
Mary Ann Gray
/s/ Ellen ChiniaraDirectorFebruary 27, 2025
Ellen Chiniara
/s/ James BoylanDirectorFebruary 27, 2025
James Boylan
/s/ Richard LindahlDirectorFebruary 27, 2025
Richard Lindahl
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.